Efruxifermin

立即咨询

Efruxifermin

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2375240-92-7

Efruxifermin 是一种Fc-FGF21融合蛋白(人 IgG1 Fc 结构域连接到修饰的人 FGF21)。与天然人 FGF21 相比，Efruxifermin 的半衰期延长，受体亲和力增强。Efruxifermin 可用于非酒精性脂肪性肝炎的研究。

生物活性

Efruxifermin is anFc-FGF21fusion protein (humanIgG1Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis^[1].

IC₅₀& Target

FGF21

体内研究
(In Vivo)

Efruxifermin (0-100 mg/kg，皮下注射，每周一次，持续4或26周)以剂量依赖的方式减少 Sprague Dawley 大鼠的体重增加^[1]。

Animal Model:	Male and female Sprague Dawley rats^[1]
Dosage:	0, 1, 10, 30, 100 mg/kg
Administration:	Subcutaneous injection, Once weekly, for 4 or 26 weeks
Result:	Significantly reduced body weight gain after 4 and 26 weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.

CAS 号

2375240-92-7

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.